Blaise A Clarke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3633885/publications.pdf

Version: 2024-02-01

147 papers	9,709 citations	38742 50 h-index	38395 95 g-index
148 all docs	148 docs citations	148 times ranked	13832 citing authors

#	Article	IF	Citations
1	Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers. International Journal of Gynecological Cancer, 2022, , ijgc-2021-003082.	2.5	0
2	Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma. Journal of Ovarian Research, 2022, 15, 50.	3.0	3
3	Interpretation of mismatch repair protein expression using obsolete criteria results in discrepancies with microsatellite instability and mutational testing results. Comment on Hechtman et al. Mod Pathol 2020; 33:871â€“879. Modern Pathology, 2021, 34, 1031-1032.	5.5	6
4	Tumor and germline next generation sequencing in high grade serous cancer: experience from a large populationâ€based testing program. Molecular Oncology, 2021, 15, 80-90.	4.6	14
5	Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging. JAMA Surgery, 2021, 156, 157.	4.3	118
6	An Integrative DNA Sequencing and Methylation Panel to Assess Mismatch Repair Deficiency. Journal of Molecular Diagnostics, 2021, 23, 242-252.	2.8	12
7	Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma. Cancer Treatment and Research Communications, 2021, 27, 100363.	1.7	1
8	Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. Gynecologic Oncology, 2021, 161, 221-227.	1.4	9
9	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data metaâ€analysis. Cancer, 2021, 127, 2409-2422.	4.1	62
10	Performance characteristics of brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed ovarian cancers.. Journal of Clinical Oncology, 2021, 39, e22525-e22525.	1.6	0
11	Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer. Cancer, 2021, 127, 3082-3091.	4.1	6
12	Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series. Gynecologic Oncology Reports, 2021, 36, 100729.	0.6	1
13	Validation of BRCA testing on cytologic samples of highâ€grade serous carcinoma. Cancer Cytopathology, 2021, 129, 907-913.	2.4	2
14	Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma. International Journal of Gynecological Pathology, 2021, 40, 116-123.	1.4	36
15	Placenta increta mimicking placental site trophoblastic tumor. International Journal of Gynecological Cancer, 2021, 31, 1481-1485.	2.5	1
16	Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma. Modern Pathology, 2020, 33, 1207-1219.	5.5	43
17	Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21. Journal of Experimental Medicine, 2020, 217, .	8.5	51
18	Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. Gynecologic Oncology, 2020, 159, 539-545.	1.4	4

#	Article	IF	Citations
19	Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer. Cancer, 2020, 126, 4886-4894.	4.1	15
20	IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function. Cancer Immunology Research, 2020, 8, 321-333.	3.4	26
21	Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers. International Journal of Gynecological Cancer, 2020, 30, 1951-1958.	2.5	5
22	Comprehensive molecular assessment of mismatch repair deficiency in Lynch-associated ovarian cancers using next-generation sequencing (NGS) panel.. Journal of Clinical Oncology, 2020, 38, 1523-1523.	1.6	2
23	Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing. Modern Pathology, 2019, 32, 1823-1833.	5.5	52
24	Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer. OncoImmunology, 2019, 8, e1665460.	4.6	27
25	Neoadjuvant therapy in gynaecological malignancies: What pathologists need to know. Journal of Clinical Pathology, 2019, 72, 102-111.	2.0	2
26	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nature Communications, 2019, 10, 558.	12.8	76
27	Metastatic low-grade endometrial stromal sarcoma of uterus presenting as a primary pancreatic tumor: case presentation and literature review. Diagnostic Pathology, 2019, 14, 30.	2.0	7
28	TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. International Journal of Gynecological Cancer, 2019, 29, 346-352.	2.5	29
29	N-Glycoproteomics of Patient-Derived Xenografts: A Strategy to Discover Tumor-Associated Proteins in High-Grade Serous Ovarian Cancer. Cell Systems, 2019, 8, 345-351.e4.	6.2	31
30	High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation. , 2019, 7, 357.		52
31	Expanding the morphological spectrum of ovarian microcystic stromal tumour. Histopathology, 2019, 74, 443-451.	2.9	24
32	International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. International Journal of Gynecological Pathology, 2019, 38, S114-S122.	1.4	52
33	A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing. American Journal of Pathology, 2018, 188, 1120-1131.	3.8	23
34	Gynaecological neoplasms in common familial syndromes (Lynch and HBOC). Pathology, 2018, 50, 222-237.	0.6	23
35	Genomic profiling identifies GPC5 amplification in association with sarcomatous transformation in a subset of uterine carcinosarcomas. Journal of Pathology: Clinical Research, 2018, 4, 69-78.	3.0	9
36	Ovarian Microcystic Stromal Tumors Are Characterized by Alterations in the Beta-Catenin-APC Pathway and May be an Extracolonic Manifestation of Familial Adenomatous Polyposis. American Journal of Surgical Pathology, 2018, 42, 137-139.	3.7	41

#	Article	IF	Citations
37	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirusâ€“Related Cervical Carcinoma. JAMA Oncology, 2018, 4, e173776.	7.1	116
38	Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Genome Medicine, 2018, 10, 81.	8.2	72
39	Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma. Clinical Cancer Research, 2018, 24, 5685-5696.	7.0	76
40	A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. Clinical Cancer Research, 2018, 24, 6168-6174.	7.0	44
41	Clinical, morphological and immunohistochemical evidence that smallâ€cell carcinoma of the ovary of hypercalcaemic type (<scp>SCCOHT</scp>) may be a primitive germâ€cell neoplasm. Histopathology, 2017, 70, 1147-1154.	2.9	36
42	Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. Journal of Clinical Oncology, 2017, 35, 1240-1249.	1.6	79
43	A distinct innate lymphoid cell population regulates tumor-associated T cells. Nature Medicine, 2017, 23, 368-375.	30.7	131
44	Ovarian carcinoma histotype in Lynch syndrome. Gynecologic Oncology Reports, 2017, 20, 140-141.	0.6	1
45	VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation. British Journal of Cancer, 2017, 116, 1065-1076.	6.4	26
46	The predictive value of nadir neutrophil count during treatment of cervical cancer: Interactions with tumor hypoxia and interstitial fluid pressure (IFP). Clinical and Translational Radiation Oncology, 2017, 6, 15-20.	1.7	16
47	Implementing a Cervical Sentinel Lymph Node Biopsy Program: Quality Improvement in Gynaecologic Oncology. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 659-667.	0.7	10
48	Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials. Expert Opinion on Orphan Drugs, 2017, 5, 71-83.	0.8	11
49	DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. American Journal of Surgical Pathology, 2017, 41, 1178-1187.	3.7	114
50	Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy. Clinical Cancer Research, 2017, 23, 925-934.	7.0	125
51	Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium.. Journal of Clinical Oncology, 2017, 35, 5522-5522.	1.6	6
52	Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. Oncotarget, 2017, 8, 84659-84670.	1.8	13
53	Uterine Clear Cell Carcinoma. Molecular Pathology Library, 2017, , 123-142.	0.1	0
54	Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in smallâ€cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. Histopathology, 2016, 69, 727-738.	2.9	52

#	Article	IF	Citations
55	Ovarian hilar proliferations resembling Sertoli cell tumours: microscopic neoplasms or nonâ€neoplastic remnants?. Histopathology, 2016, 68, 596-602.	2.9	6
56	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. Gynecologic Oncology, 2016, 141, 559-563.	1.4	25
57	Gynecologic Pathology. Surgical Pathology Clinics, 2016, 9, ix-x.	1.7	0
58	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Medicine, 2016, 8, 109.	8.2	211
59	Prophylactic Gynecologic Specimens from Hereditary Cancer Carriers. Surgical Pathology Clinics, 2016, 9, 307-328.	1.7	3
60	Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 111-117.	0.8	25
61	Precursors of High-Grade Serous Carcinoma. , 2016, , 3-22.		0
62	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). Gynecologic Oncology, 2016, 141, 148-154.	1.4	34
63	Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.. Journal of Clinical Oncology, 2016, 34, 1532-1532.	1.6	2
64	Integration of somatic molecular profiling for rare epithelial gynaecologic cancer patients.. Journal of Clinical Oncology, 2016, 34, 5509-5509.	1.6	0
65	Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome.. Journal of Clinical Oncology, 2016, 34, 5579-5579.	1.6	0
66	Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients (pts) with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium.. Journal of Clinical Oncology, 2016, 34, 5564-5564.	1.6	0
67	P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes.. Journal of Clinical Oncology, 2016, 34, 5550-5550.	1.6	0
68	Microscopic extraovarian sex cord proliferations: an undescribed phenomenon. Histopathology, 2015, 66, 555-564.	2.9	28
69	Mutations in <scp>IDH</scp>1 and <scp>IDH</scp>2 are not present in sporadic ovarian sex cordâ€“stromal tumours. Histopathology, 2015, 66, 897-898.	2.9	0
70	Inâ€depth molecular profiling of the biphasic components of uterine carcinosarcomas. Journal of Pathology: Clinical Research, 2015, 1, 173-185.	3.0	70
71	Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. Gynecologic Oncology, 2015, 136, 311-316.	1.4	9
72	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Modern Pathology, 2015, 28, 1101-1122.	5.5	164

#	Article	IF	Citations
73	A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecologic Oncology, 2015, 137, 216-222.	1.4	65
74	Chromosomal instability as a prognostic marker in cervical cancer. BMC Cancer, 2015, 15, 361.	2.6	18
75	Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers. Gynecologic Oncology, 2015, 139, 268-274.	1.4	50
76	A phase I/II study of ipilimumab in women with metastatic or recurrent cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.. Journal of Clinical Oncology, 2015, 33, 3061-3061.	1.6	16
77	Developing a Prognostic Micro-RNA Signature for Human Cervical Carcinoma. PLoS ONE, 2015, 10, e0123946.	2.5	42
78	Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status.. Journal of Clinical Oncology, 2015, 33, 1532-1532.	1.6	0
79	Molecular profiling and targeted therapy in advanced endometrial cancer.. Journal of Clinical Oncology, 2015, 33, 5589-5589.	1.6	0
80	ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Modern Pathology, 2014, 27, 255-261.	5.5	110
81	Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer, 2014, 120, 3932-3939.	4.1	114
82	Molecular Profiling and Clinical Outcome of High-Grade Serous Ovarian Cancer Presenting with Low- versus High-Volume Ascites. BioMed Research International, 2014, 2014, 1-9.	1.9	27
83	Canadian Association of Pathologistsâ€“Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry. American Journal of Clinical Pathology, 2014, 142, 629-633.	0.7	12
84	Review of findings in prophylactic gynaecological specimens in <scp>L</scp>ynch syndrome with literature review and recommendations for grossing. Histopathology, 2014, 65, 228-239.	2.9	29
85	No small surpriseÂâ€“Âsmall cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour. Journal of Pathology, 2014, 233, 209-214.	4.5	117
86	Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes and Cancer, 2014, 53, 845-856.	2.8	128
87	Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer, 2014, 120, 603-610.	4.1	64
88	Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer, 2014, 14, 982.	2.6	27
89	The Histomorphology of Lynch Syndromeâ€“associated Ovarian Carcinomas. American Journal of Surgical Pathology, 2014, 38, 1173-1181.	3.7	108
90	Current Morphologic Criteria Perform Poorly in Identifying Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-associated Uterine Leiomyomas. International Journal of Gynecological Pathology, 2014, 33, 560-567.	1.4	25

#	Article	IF	Citations
91	Displaced Granulosa Cells Within the Ovarian Stroma in a BRCA1 Mutation Carrier. International Journal of Gynecological Pathology, 2014, 33, 423-424.	1.4	2
92	Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. Gynecologic Oncology, 2014, 133, 229-233.	1.4	73
93	ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Human Pathology, 2014, 45, 1258-1268.	2.0	34
94	A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Investigational New Drugs, 2014, 32, 243-249.	2.6	70
95	Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. Journal of Pathology, 2014, 232, 473-481.	4.5	81
96	Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nature Genetics, 2014, 46, 438-443.	21.4	383
97	Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nature Genetics, 2014, 46, 427-429.	21.4	298
98	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nature Genetics, 2014, 46, 1166-1169.	21.4	188
99	Genotype matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).. Journal of Clinical Oncology, 2014, 32, 5506-5506.	1.6	2
100	Adjuvant radiation for patients (pts) with high-grade serous ovarian cancer (HGSC) and T-cell infiltration.. Journal of Clinical Oncology, 2014, 32, 5543-5543.	1.6	0
101	The CXCL12/CXCR4 pathway, bone marrow-derived myeloid cells, and survival in locally advanced cervical cancer.. Journal of Clinical Oncology, 2014, 32, 11122-11122.	1.6	0
102	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 1182-1191.	2.6	50
103	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncology, The, 2013, 14, 853-862.	10.7	335
104	The Significance of Tumoral ERCC1 Status in Patients With Locally Advanced Cervical Cancer Treated With Chemoradiation Therapy: A Multicenter Clinicopathologic Analysis. International Journal of Radiation Oncology Biology Physics, 2013, 85, 721-727.	0.8	15
105	Uterine adenosarcomas: A dual-institution update on staging, prognosis and survival. Gynecologic Oncology, 2013, 131, 634-639.	1.4	36
106	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with <scp>HER2</scp> targeting in 19% of carcinomas. Journal of Pathology, 2013, 229, 111-120.	4.5	169
107	Neuroendocrine tumors of the gynecologic tract: Select topics. Seminars in Diagnostic Pathology, 2013, 30, 224-233.	1.5	61
108	Endometrial sarcomas: an immunohistochemical and JAZF1 re-arrangement study in low-grade and undifferentiated tumors. Modern Pathology, 2013, 26, 95-105.	5.5	49

#	Article	IF	Citations
109	Hypoxic Activation of the PERK/eIF2Î± Arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3. Clinical Cancer Research, 2013, 19, 6126-6137.	7.0	105
110	Identifying Lynch Syndrome in Patients With Ovarian Carcinoma. Advances in Anatomic Pathology, 2013, 20, 378-386.	4.3	52
111	A Triage Assessment Strategy for the Management of Women With Endometrial Cancer. Journal of Obstetrics and Gynaecology Canada, 2013, 35, 348-354.	0.7	0
112	Biologically-Targeted Detection of Primary and Micro-Metastatic Ovarian Cancer. Theranostics, 2013, 3, 420-427.	10.0	24
113	MicroRNA-196b Regulates the Homeobox B7-Vascular Endothelial Growth Factor Axis in Cervical Cancer. PLoS ONE, 2013, 8, e67846.	2.5	60
114	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. Journal of Clinical Oncology, 2013, 31, 11002-11002.	1.6	16
115	Screening for Lynch syndrome in unselected women with endometrial cancer.. Journal of Clinical Oncology, 2013, 31, 5508-5508.	1.6	0
116	Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx). Cancers, 2012, 4, 821-845.	3.7	44
117	Prevalence of Loss of Expression of DNA Mismatch Repair Proteins in Primary Epithelial Ovarian Tumors. International Journal of Gynecological Pathology, 2012, 31, 524-531.	1.4	66
118	Identifying Lynch Syndrome in Patients With Endometrial Carcinoma. Advances in Anatomic Pathology, 2012, 19, 231-238.	4.3	51
119	Recurrent SomaticDICER1Mutations in Nonepithelial Ovarian Cancers. New England Journal of Medicine, 2012, 366, 234-242.	27.0	401
120	Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses. Journal of the National Cancer Institute, 2012, 104, 1503-1513.	6.3	231
121	Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205.	4.4	676
122	Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Cancer Treatment Reviews, 2012, 38, 767-775.	7.7	46
123	Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation. Cancer, 2012, 118, 3105-3115.	4.1	50
124	Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. Journal of Translational Medicine, 2012, 10, 33.	4.4	93
125	Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutationâ€positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer, 2012, 118, 681-688.	4.1	71
126	Molecular determinants of outcome with mTOR inhibition in endometrial cancer (EC).. Journal of Clinical Oncology, 2012, 30, 5010-5010.	1.6	7

#	Article	IF	Citations
127	Prognostic significance of high-risk human papilloma virus (HPV), p16, and p53 status in women with vulvar squamous cell carcinoma (VSCC).. Journal of Clinical Oncology, 2012, 30, 5105-5105.	1.6	0
128	Brief family history questionnaire for identification of Lynch syndrome in women with newly diagnosed endometrial cancer.. Journal of Clinical Oncology, 2012, 30, 5026-5026.	1.6	0
129	Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors. Cancer Research, 2011, 71, 3364-3376.	0.9	662
130	Histologic Artifacts in Abdominal, Vaginal, Laparoscopic, and Robotic Hysterectomy Specimens. American Journal of Surgical Pathology, 2011, 35, 115-126.	3.7	74
131	Tubulo-squamous Polyp With Mucinous and Goblet Cell Differentiation. International Journal of Gynecological Pathology, 2011, 30, 518-519.	1.4	12
132	Ovarian immature teratoma: Treatment and outcome in a single institutional cohort. Gynecologic Oncology, 2011, 123, 50-53.	1.4	33
133	In-Depth Proteomics of Ovarian Cancer Ascites: Combining Shotgun Proteomics and Selected Reaction Monitoring Mass Spectrometry. Journal of Proteome Research, 2011, 10, 2286-2299.	3.7	72
134	Calculator for ovarian carcinoma subtype prediction. Modern Pathology, 2011, 24, 512-521.	5.5	95
135	Letter to the editor regarding â€˜Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expressionâ€˜. Modern Pathology, 2011, 24, 1281-1282.	5.5	6
136	Endometrial Giant Cell Carcinoma: A Case Series and Review of the Spectrum of Endometrial Neoplasms Containing Giant Cells. American Journal of Surgical Pathology, 2010, 34, 1132-1138.	3.7	20
137	Leiomyosarcoma of the Broad Ligament With Osteoclast-like Giant Cells and Rhabdoid Cells. International Journal of Gynecological Pathology, 2010, 29, 432-437.	1.4	7
138	Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. Journal of Clinical Pathology, 2010, 63, 410-415.	2.0	93
139	Cryptococcemia Resulting in an Incomplete Abortion in an HIV-Positive Patient. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, e97-e99.	1.9	3
140	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern Pathology, 2009, 22, 393-402.	5.5	241
141	Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. Human Pathology, 2009, 40, 1070-1081.	2.0	147
142	Mutation ofFOXL2in Granulosa-Cell Tumors of the Ovary. New England Journal of Medicine, 2009, 360, 2719-2729.	27.0	706
143	Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. Seminars in Diagnostic Pathology, 2009, 26, 165-176.	1.5	25
144	Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Human Pathology, 2008, 39, 1239-1251.	2.0	231

#	Article	IF	Citations
145	Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Modern Pathology, 2007, 20, 1156-1165.	5.5	58
146	Clear cell (glycogen-rich) gastric adenocarcinoma. Annals of Diagnostic Pathology, 2004, 8, 69-73.	1.3	29
147	Systemic Anaplastic Large Cell Lymphoma Presenting With Conjunctival Involvement. JAMA Ophthalmology, 2003, 121, 568.	2.4	32